China-based Changchun High & New Technology Industries (Group) Inc. (SHE: 000661) announced its subsidiary GenScipt Biotech Corp. receiving approval to initiate a clinical study for its GenSci120 in rheumatoid arthritis (RA) in the United States. This marks a significant step forward in the development of this innovative biologic product for autoimmune diseases.
Drug Mechanism and Applications
GenSci120 is a Category 1 biologic product designed to bind to PD-1 and activate the PD-1 inhibitory signaling pathway and ADCC effect. This mechanism allows it to inhibit or kill pathogenic T cells, offering a targeted immunosuppressive effect. The monoclonal antibody has previously been approved for clinical studies in adult systemic lupus erythematosus, adult primary Sjogren’s syndrome, inflammatory bowel disease, and rheumatoid arthritis in China.-Fineline Info & Tech
Leave a Reply